mallinckrodt liked that acktar had 19 different uses.ven at the time of the acquisition there were questions whether insurance companies would continue to provide reimbursement for it, especially after that jack-up in price. then there was legislation over the generic version, tenactin. mallinckrodt is now caught up in the political firestorm over drug price increases. there's a sense these prices will be rolled back because of an angry congress and candidates for president, including hillary clinton. mallinckrodt nevertheless decided to plow through and buy questcore, closed on the deal in august of last year. at the time mallinckrodt's ceo came on the show and told us he thought their main drug was undervalued. take a listen. why was this a controversial acquisition by some? why did i keep hearing that acktar was not a great drug or there won't be a reimbursement? >> this is a drug that's really delivering value for patients. we just felt it was mischaracterized. we felt we were the best owners. as we went through our due diligence pro